Schizophrenia in children and adolescents

Clinical Aspects of Psychopharmacology in Childhood and Adolescence

Volumn , Issue , 2011, Pages 145-161

  Nazeer, Ahsan ^a   Calles, Joseph L ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85029948886     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (56)

1. Jacobsen LK, Rapoport JL. Research update: Childhood onset schizophrenia: Implication of clinical and neurobiological research. [J. Child Psychol Psychiat] 1998;39:101-13.
2. Kuhn R (translated by Cahn CH): Eugen Bleuler’s concepts of psychopathology. [Hist Psychiatry] 2004;15:361-6.
3. Bender, L. Childhood schizophrenia. [Psychiatr Q]. 1953;27(4):663-81.
4. Rutter M. Childhood schizophrenia reconsidered. [J Autism Child Schizophr] 1972;2(4):315-37.
5. McGrath JJ. Variations in the incidence of schizophrenia: data versus dogma. [Schizophr Bull] 2006;32(1):195-7.
6. Remschmidt HE, Schulz E, Martin M, Warnke A, Trott GE. Childhood-onset schizophrenia: history of the concept and recent studies. [Schizophr Bull]. 1994;20(4):727-45.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text rev. Washington, DC: [APA], 2000.
8. Del Beccaro MA, Burke P, McCauley E. Hallucinations in children: a follow-up study. [J Am Acad Child Adolesc Psychiatry] 1988;27:462-5.
9. Tsuang MT, Faraone SV. Diagnostic concepts and the prevention of schizophrenia. [Can J Psychiatry] 2002;47(6):515-7.
10. Tsuang MT, Stone WS, Faraone SV. Understanding predisposition to schizophrenia: toward intervention and prevention. [Can J Psychiatry] 2002;47(6):518-26.
11. Strous RD, Alvir JM, Robinson D, Gal G, Sheitman B, Chakos M, Lieberman JA. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. [Schizophr Bul] 2004;30(2):265-78.
12. Karp BI, Garvey M, Jacobsen LK, et al. Abnormal neurologic maturation in adolescents with early-onset schizophrenia. [Am J Psychiatry] 2001;158(1):118-22.
13. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. [Neuropsychology] 1998;12(3):426-45.
14. Lewis R. Should cognitive deficit be a diagnostic criterion for schizophrenia? [J Psychiatry Neurosci] 2004;29:102-13.
15. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. [Arch Gen Psychiatry] 2008;65(1):28-37.
16. McClellan J, Werry J, Bernet W, Arnold V, Beitchman J, Benson RS, et al. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. [J Am Acad Child Adoles Psychiatry] 2001; 40(7):4S-23S
17. Zametkin AJ, Ernst M, Silver R. Laboratory and diagnostic testing in child and adolescent psychiatry: A review of the past ten years. [J Am Acad Child Adoles Psychiatry] 1998;37:464-72
18. Lehman AF, Lieberman JA, Dixon LB et al. Practice guidelines for the treatment of patients with schizophrenia, second edition. [Am J Psychiatry] 2004;161:S1-56.
19. McKay D, Gorrell J, Cornish A et al. Let’s get physical: an audit of medical practice in first episode psychosis. [Australas Psychiatry] 2006;14:146-9.
20. Mueller C, Rufer M, Moergeli H, Bridler R. Brain imaging in psychiatry - a study of 435 psychiatric in-patients at a university clinic. [Acta Psychiatr Scand] 2006; 114:91-100.
21. Erhart SM. Young AS. Marder SR. Mintz J. Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry. [J Clin Psychiatry] 2005;66:968-73.
22. Lubman DI, Velakoulis D, McGorry PD et al. Incidental radiological findings on brain magnetic resonance imaging in first-episode psychosis and chronic schizophrenia. [Acta Pscyhiatr Scand] 2002; 106:331-6.
23. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. [JAMA] 1990;264:2511-8.
24. Volkow ND. Substance use disorders in schizophrenia-clinical implications of comorbidity. [Schizophr Bull] 2009;35(3):469-72
25. Rezvani AH, Levin ED. Cognitive effects of nicotine. [Biol Psychiatry] 2001; 49:258-67.
26. Mulholland C, Cooper S.The symptom of depression in schizophrenia and its management [Adv. Psychiatr. Treat]. 2000;6:169-77.
27. Siris, SG. Assessment and treatment of depression in schizophrenia. [Psychiatr Ann] 1994;24,463-7.
28. Muller JE, Koen L, Soraya S, Emsley RA, Stein DJ. Anxiety disorders and schizophrenia. [Curr Psychiatry Rep]. 2004;6:255-61.
29. Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A: Obsessive-compulsive symptoms induced by atypical antipsychotics: a review of the reported cases. [Prog Neuropsychopharmacol Biol Psychiatry] 2003;27:333-46.
30. BA Palmer, VS Pankratz, JM Bostwick. The lifetime risk of suicide in schizophrenia: A reexamination. [Arch Gen Psychiatry] 2005;62: 247-53.
31. Calderoni D, Wudarsky M, Bhangoo R, et al. Differentiating childhood onset schizophrenia from psychotic mood disorders. [J Am Acad Child Adolesc Psychiatry] 2001;40(10):1190-6.
32. Armenteros JL, Davies M. Antipsychotics in early onset Schizophrenia: Systematic review and metaanalysis. [Eur Child Adolesc Psychiatry]. 2006;15(3): 141-8.
33. Lieberman JA, Stroup TS, McEvoy JP. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. [N Engl J Med]. 2005;353(12):1209-23.
34. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of effect on quality of life of second vs. first generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). [Arch Gen Psychiatry]. 2006;63:1079-87.
35. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Licberman A. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. [Neuropsychopharmacology] 2004;29:133-45.
36. Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. [J Am Acad Child Adolesc Psychiatry] 2009;48(1):60-70.
37. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. [Am J Psychiatry] 2008;165:1420-31.
38. Lieberman JA. Metabolic changes associated with antipsychotic use. [Prim Care Companion J Clin Psychiatry] 2004;6:8-13.
39. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. [Schizophr Res] 2006;83(1):87-93.
40. Consensus development conference on antipsychotic drugs and obesity and diabetes. [Diabetes Care] 2004;27(2):596-601
41. Laita P, Cifuentes A, Doll A, Llorente C, Cortés I, Parellada M, Moreno D, et al. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. [J Child Adolesc Psychopharmacol]. 2007;17(4):487-502.
42. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. [Ann Clin Psychiatry] 2002;14:59-64
43. Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M. et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. [Child Adolesc Psychiatr Clin N Am] 2006;15(1):177-206.
44. Castro-Fornieles J, Parellada M, Soutullo CA, Baeza I, Gonzalez-Pinto A, Graell M, Paya B, et al. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. [J Child Adolesc Psychopharmacol] 2008;18(4):327-36.
45. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. [J Clin Psychopharmacol] 2004;24:S7-14.
46. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. [Can J Psychiatry] 2006;1;51(8):480-91.
47. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. [CNS Drugs] 2005;19:1-93.
48. Poulin MJ, Cortese L, Williams R, Wine N, McIntyre RS. Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring. [Can J Psychiatry] 2005;50(9):555-62.
49. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. [Diabetes Care] 2004;27:596-601.
50. Miller AL, Weiden PJ. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. [J Psychiatr Pract] 2001;7:41-68.
51. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. [Am J Psychiatry] 2004;161:1334-49.
52. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. [Can J Psychiatry] 2006 Jul;51(8):492-501.
53. Grundy SM, Hansen B, Smith SC Jr., Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. [Circulation] 2004;3:109(4):551-6.
54. Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. [Prim Care Diabetes]. 2009;3(1):5-15.
55. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Herald A, et al. Minimizing metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. [J Psychopharmacol] 2007;21:357-73.
56. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G. et al. Psychological treatments in schizophrenia: Metaanalysis of family intervention and cognitive behavior therapy. [Psychol Med] 2002;32,763-82.